Celldex Therapeutics Inc. (CLDX)
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $0.85 per share a year ago.
Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?
Here is how Celldex Therapeutics (CLDX) and Illumina (ILMN) have performed compared to their sector so far this year.
Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss
Celldex Therapeutics NASDAQ: CLDX said a Phase 2 trial of barzolvolimab in prurigo nodularis did not meet its primary or secondary endpoints, prompting the company to discontinue development of the drug in that indication while continuing to focus on ongoing late-stage urticaria studies.
Celldex to stop skin disease study after trial setback
Celldex Therapeutics said on Tuesday it would discontinue the development of its experimental drug for a skin disease after it failed to meet the main goal and key secondary goals in a mid-stage study, sending its shares down over 7% in extended trading.
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $1.1. This compares to a loss of $0.81 per share a year ago.
Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?
The mean of analysts' price targets for Celldex (CLDX) points to a 76.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $0.54 per share a year ago.
Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.56 per share a year ago.
Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.57 per share a year ago.
Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.81 per share a year ago.
CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study
Celldex stock falls due to safety concerns related to the treatment of urticaria patients with barzolvolimab in a phase II study, despite robust efficacy data.
Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.65 per share a year ago.
